TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04748250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: Standard acupuncture needle which is 3 cm long with diameter o.3 mm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: Standard acupuncture needle which is 3 cm long with diameter o.3 mm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens
Description: 100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens
Description: 100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
Study: NCT02256150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CTX)
Study: NCT03696498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin restoration (1 step)
Description: Permanent resin restoration is placed on top of the partial removed caries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin restoration (2 steps)
Description: A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
Study: NCT03831607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
Study: NCT03342352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally at the protocol-defined dose twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for epacadostat administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab administered intravenously at the protocol-defined dose weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
Study: NCT00229580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 session brief intervention with health behavior feedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Study: NCT01825278

Intervention type: DEVICE
Intervention: ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA
Description: Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
Study: NCT04104074

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
Study: NCT02103374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovent + Bricanyl or Atrovent + Ventoline
Description: 3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule lactose during 48 weeks
Study: NCT01328262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calculated red blood cell transfusion
Description: The subjects receive an amount of red blood cells that has been calculated from their body surface area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard red blood cell transfusion
Description: The subjects in this group receive the prescribed number of red blood cell units.
Study: NCT03160469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intragastric Elipse Device
Description: Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less.
Study: NCT01878669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01305603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Injection under ultrasound-guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: Injection under ultrasound-guidance
Study: NCT01592942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Histoacryl
Description: cyanoacrylate glue fixation of mesh 1 ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progrip
Description: self-gripping mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sutures (prolene 3-0)
Description: non-absorbable suture fixation 3-0
Study: NCT01790763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Keramatrix
Description: Dressing for second degree burn
Study: NCT04577079

Intervention type: DEVICE
Intervention: Evaluation of the need of emergency medical services
Description: The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
Study: NCT04878744

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shmapped
Description: Novel app-based intervention to improve wellbeing in patients with common mental health problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shmapped
Description: Novel app-based intervention to improve wellbeing in patients with common mental health problems.
Study: NCT05186441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DMPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DMPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DLPFC iTBS
Description: The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
Study: NCT03024138

Intervention type: RADIATION
Intervention: Repeat CT scan
Study: NCT01052961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: oseltamivir 150 mg bd for 5 days
Study: NCT01605942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Drug Delivery System
Description: Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug Delivery System
Description: Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
Study: NCT03641846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DornierAries2 LiST device + 5 mg Tadalafil
Description: All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DornierAries2 LiST device + Placebo Pill
Description: All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
Study: NCT02033213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive group
Description: A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal group
Description: A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
Study: NCT01866033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Treatment A)
Description: 560 mg capsules administered by mouth on Day 1, Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Treatment B)
Description: 560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765 (Treatment C)
Description: 140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C6 PCI-32765 (reference)
Description: 100 mcg administered intravenously 2 h after study drug
Study: NCT03130426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Description: Dose is titrated to achieve fasting normoglycemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Dose is titrated to 2000 mg daily or maximal tolerated dose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
Study: NCT02744612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT01790763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex
Description: Dressing for second degree wound
Study: NCT01766349

Intervention type: BEHAVIORAL
Intervention: respiratory muscle performance
Description: Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
Study: NCT02714361

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 supplement
Description: 1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 65% olive oil capsules daily over 8 weeks (56 days)
Study: NCT04206553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching dupilumab without active substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCS)
Description: Prednisone or prednisolone per standard of care to obtain control of disease activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCS)
Description: Prednisone or prednisolone per standard of care to obtain control of disease activity.
Study: NCT01748474

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental oxygen via a mask

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via a mask
Study: NCT02834585

Intervention type: OTHER
Intervention: Ultrasound

Intervention type: OTHER
Intervention: Ultrasound
Study: NCT02094027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self Help
Description: A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual
Description: Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
Study: NCT03085004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Study: NCT04264598

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercialized sIPV
Description: The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercialized IPV
Description: The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study: NCT01457066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigator Intervention
Description: Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
Study: NCT01045642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Magnesium DR Capsules 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole Magnesium DR Capsules 20 mg
Study: NCT00597766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Lidocaine
Description: Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Lidocaine
Description: Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone + Lidocaine
Description: High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
Study: NCT03577704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+Gemcitabine+Cisplatin
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+Paclitaxel+Carboplatin
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07+mFOLFOX6
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly.
Study: NCT03566823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ontamalimab
Description: Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
Study: NCT01622361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin+Cyclophosphamide>Docetaxel
Description: 1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa with Tamoxifen
Description: 1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday
Study: NCT05298280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pendulum appliance
Description: In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligners
Description: The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
Study: NCT02310945

Intervention type: OTHER
Intervention: Physiotherapy
Description: Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy